SIFI S.p.A. Acquired by Faes Farma for €270M

Deal News | Jun 13, 2025 | Hogan Lovells

Hogan Lovells advised the founding shareholders of SIFI S.p.A. and 21 Invest on the sale of SIFI to Faes Farma, valuing SIFI at €270 million. The deal includes deferred earn-out components tied to the commercialization of the orphan drug Akantion in Europe and other markets, contingent upon FDA's approval in the U.S. SIFI S.p.A. is known for its pharmaceutical, surgical, and medical devices targeting eye care, strengthening Faes Farma's market position in ocular health. Key legal advisory roles were provided by Hogan Lovells, with a comprehensive team covering corporate, FDA regulatory, employment, and intellectual property aspects.

Sectors

  • Pharmaceuticals
  • Medical Devices

Geography

  • Italy – SIFI S.p.A., the target of the acquisition, is based in Italy.
  • Spain – Faes Farma, the acquiring company, is headquartered in Spain.
  • United States – The transaction involves regulatory considerations in the US, particularly FDA approval for SIFI's products.

Industry

  • Pharmaceuticals – The article is primarily involved in the pharmaceutical industry, focusing on eye care products and drug development.
  • Medical Devices – SIFI S.p.A.'s product portfolio includes surgical and medical devices for eye care, making this industry classification relevant.

Financials

  • €270 million – The enterprise value of SIFI S.p.A. in the acquisition by Faes Farma.

Participants

NameRoleTypeDescription
SIFI S.p.A.Target CompanyCompanyAn Italian company specializing in pharmaceutical products and medical devices for eye care.
Faes FarmaAcquirerCompanyA Spanish pharmaceutical company expanding its market in eye care products.
Hogan LovellsLegal AdvisorCompanyA multinational law firm advising on the corporate, regulatory, and IP aspects of the transaction.
21 InvestSelling CompanyCompanyThe private equity firm involved in facilitating the sale of SIFI S.p.A.